Faget Quoted in MedTech Dive on the FDA’s Response to the COVID Crisis
March 15, 2021
MedTech Dive
Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
People
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.